PIRS News and Press, Pieris Pharmaceuticals Inc. From 08/24/23

2023-08-24 13:10:24 ET Are you looking for the best penny stocks to buy ? You’re not alone; many traders are showing a renewed interest in this exciting market. The current fluctuations in the stock market have sparked a fresh wave of risk-taking. This has led to a growing curios...

2023-08-22 10:51:53 ET If you’re looking for penny stocks to buy this week, you’ve got your work cut out for yourself. Plenty of headwinds will be faced, including more tech earnings and Friday’s speech from Fed Chair Jerome Powell. But amid the noise, there emerge new ...

2023-08-17 10:51:44 ET More on Pieris Pharma Pieris sinks 60% as AstraZeneca halts mid-stage trial for Asthma candidate Pieris spikes 11% on data for gastric cancer candidate Pieris stock slumps ~15% after FY22 sees fall in revenue Pieris to get $5M as Seagen...

BOSTON, MA / ACCESSWIRE / August 17, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases and cancer, today announced that the Company ha...

BOSTON, MA / ACCESSWIRE / July 18, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases and cancer, today provided a strategic update foll...

BOSTON, MA / ACCESSWIRE / June 21, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases and cancer indications, announced that partner Ast...

BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory and cancer diseases, today announced that Stephen Yoder, p...

BOSTON, MA / ACCESSWIRE / May 22, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the pre...

BOSTON, MA / ACCESSWIRE / May 21, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the p...

2023-05-17 00:55:30 ET Summary Expanding Elarekibep (AZD1402) trial finally has active/completed sites. Major investment risk exists because of the Company's cash burn rate. Potential deals on PRS-220 and PRS-343 could bolster the Company's balance sheet. The Company's low...